Pre-order Enquiry
Request Free Sample
Global Cutaneous Fibrosis Treatment Market Size, Status and Forecast 2019-2025
SKU ID : QYR-14501997 | Publishing Date : 01-Aug-2019 | No. of pages : 91
Cutaneous fibrosis is the accumulation of extracellular matrix (ECM) components in the dermis, leading to compromised function and altered architecture of the dermis. Development of fibrosis occurs naturally during scar formation in wound repair or is a pathological process in pro-fibrotic diseases.
Cutaneous fibrosis is a fundamental feature of fatty skin sclerosis and is associated with increased levels of the cytokine transforming growth factor-β,186. This growth factor may be derived from activated leukocytes, recruit’s macrophages and fibroblasts into the tissue and leads to the production of extracellular matrix proteins by dermal fibroblasts. The goal of skin fibrosis treatment is the restore abnormally activated dermal fibroblasts producing the excessive amount of extracellular matrix, which is generally a final consequence of the complex disease process including the activation of vascular and immune systems.
The prototype of fibrotic skin disease is scleroderma, which can be divided into whole body and local forms. Progressive systemic sclerosis (PSS) is a widespread connective tissue disease in which the fibrotic process affects not only the skin but also the lungs, heart, kidneys and gastrointestinal tract.
The classification of Cutaneous Fibrosis Treatment includes Immunotherapy, Corticosteroids, Anti-Fibrotic Drugs and Immunoglobulins. And the proportion of Immunotherapy in 2018 is about 48.94%. Cutaneous Fibrosis Treatment is widely in Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies. The proportion of Hospitals Pharmacies in 2018 is about 54.74%.Europe is the largest consumption place, with a consumption market share nearly 32.17% in 2018. Following Europe, North America is the second largest consumption place with the consumption market share of 30.35%. Market competition is intense. AbbVie, Bayer, Merck, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, Roche, GlaxoSmithKline, Pfizer, Novartis, LEO Pharma, Actelion. are the leaders of the industry. Regional players in the cutaneous fibrosis treatment market also hold significant share which makes the cutaneous fibrosis treatment market highly fragmented.
In 2018, the global Cutaneous Fibrosis Treatment market size was 475.1 million US$ and it is expected to reach 723.7 million US$ by the end of 2025, with a CAGR of 6.2% during 2019-2025.
This report focuses on the global Cutaneous Fibrosis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cutaneous Fibrosis Treatment development in North America and Europe..
The key players covered in this study
AbbVie
Bayer
Merck
Bristol-Myers Squibb
Sanofi
Boehringer Ingelheim
Roche
GlaxoSmithKline
Pfizer
Novartis
LEO Pharma
Actelion
Market segment by Type, the product can be split into
Immunotherapy
Corticosteroids
Anti-Fibrotic Drugs
Immunoglobulins
In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
Market segment by Application, split into
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
Market segment by Regions/Countries, this report covers
North America
Europe
The study objectives of this report are:
To analyze global Cutaneous Fibrosis Treatment status, future forecast, growth opportunity, key market and key players.
To present the Cutaneous Fibrosis Treatment development in North America and Europe..
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Cutaneous Fibrosis Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Cutaneous fibrosis is a fundamental feature of fatty skin sclerosis and is associated with increased levels of the cytokine transforming growth factor-β,186. This growth factor may be derived from activated leukocytes, recruit’s macrophages and fibroblasts into the tissue and leads to the production of extracellular matrix proteins by dermal fibroblasts. The goal of skin fibrosis treatment is the restore abnormally activated dermal fibroblasts producing the excessive amount of extracellular matrix, which is generally a final consequence of the complex disease process including the activation of vascular and immune systems.
The prototype of fibrotic skin disease is scleroderma, which can be divided into whole body and local forms. Progressive systemic sclerosis (PSS) is a widespread connective tissue disease in which the fibrotic process affects not only the skin but also the lungs, heart, kidneys and gastrointestinal tract.
The classification of Cutaneous Fibrosis Treatment includes Immunotherapy, Corticosteroids, Anti-Fibrotic Drugs and Immunoglobulins. And the proportion of Immunotherapy in 2018 is about 48.94%. Cutaneous Fibrosis Treatment is widely in Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies. The proportion of Hospitals Pharmacies in 2018 is about 54.74%.Europe is the largest consumption place, with a consumption market share nearly 32.17% in 2018. Following Europe, North America is the second largest consumption place with the consumption market share of 30.35%. Market competition is intense. AbbVie, Bayer, Merck, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, Roche, GlaxoSmithKline, Pfizer, Novartis, LEO Pharma, Actelion. are the leaders of the industry. Regional players in the cutaneous fibrosis treatment market also hold significant share which makes the cutaneous fibrosis treatment market highly fragmented.
In 2018, the global Cutaneous Fibrosis Treatment market size was 475.1 million US$ and it is expected to reach 723.7 million US$ by the end of 2025, with a CAGR of 6.2% during 2019-2025.
This report focuses on the global Cutaneous Fibrosis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cutaneous Fibrosis Treatment development in North America and Europe..
The key players covered in this study
AbbVie
Bayer
Merck
Bristol-Myers Squibb
Sanofi
Boehringer Ingelheim
Roche
GlaxoSmithKline
Pfizer
Novartis
LEO Pharma
Actelion
Market segment by Type, the product can be split into
Immunotherapy
Corticosteroids
Anti-Fibrotic Drugs
Immunoglobulins
In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
Market segment by Application, split into
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
Market segment by Regions/Countries, this report covers
North America
Europe
The study objectives of this report are:
To analyze global Cutaneous Fibrosis Treatment status, future forecast, growth opportunity, key market and key players.
To present the Cutaneous Fibrosis Treatment development in North America and Europe..
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Cutaneous Fibrosis Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
